Handa Pharmaceuticals Inc.

Handa Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing drugs for various diseases in the United States. Its offerings include ONCORE, a proprietary drug delivery technology designed to improve patient compliance and safety of tyrosine kinase inhibitors in oncology; Phyrago, an oral kinase inhibitor for chronic myeloid leukemia and acute lymphoblastic leukemia; Tascenso ODT for multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. The company also provides Quetiapine XR for schizophrenia, Dexlansoprazole DR capsules for erosive esophagitis and heartburn associated with symptomatic non-erosive gastroesophageal reflux disease, HND-004 for diabetes, Varenicline tablet and HND-032 for smoking cessation, and HND-026, a GI drug. Founded in 2014, Handa Pharmaceuticals is headquartered in Tainan City, Taiwan.